静脉应用尿激酶在治疗急性心肌梗塞中的价值

THE VALUE OF INTRAVENOUS APPLICATION OF UROKINASE IN TREATMENT OF ACUTE MYOCARDIAL INFARCTION

本文研究尿激酶治疗34例心肌梗塞(甲组)和38例对照(乙组)的心电图、二维超声心动图、冠状动脉造影和1年随访情况。结果发现,甲组的缺血相关动脉通畅率(68%)高于乙组(37%),侧支循环优于乙组(P<0.01),心室功能损害较乙组轻。但心肌梗塞后心绞痛、再梗塞发生率高于乙组(P<0.05),尽管甲组的近期病死率明显低于乙组(P<0.05),但两者远期病死率无显著差异(P>0.05)。

The ECGs, Two-dimensional echocardiograph, coronary angiograph and one year fellow-up findings were studied in 34 patients with acute myocardial infarction (MI) receiving urokinase (U. K., Group Ⅰ)and 38 patients with MI without receiving U. K. (group Ⅱ). The results indicated that group Ⅰ had a higher rate of ischemic related artery pateney,better collateral circulation, and better left ventricular function than group Ⅱ(p<0.01). But the incidence of postinfarct angina peetoris and reinfarction rate were higher in group Ⅰ than that in grorp Ⅱ. Although group Ⅰ had a lower short-term mortality than group Ⅱ there is no significant difference between the two groups in longterm mortality.